Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2006-03-21
2006-03-21
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093200, C424S215100, C424S001330, C424S131100, C424S001650, C424S142100, C424S159100, C424S174100, C424S177100, C424S205100, C435S325000, C435S235100, C435S336000, C435S002000, C435S948000, C514S04400A, C514S011400
Reexamination Certificate
active
07014847
ABSTRACT:
The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The method comprises suppressing or otherwise inhibiting the immune system of the mammal and, concurrently or subsequently, administering to the proliferating cells an effective amount of one or more reoviruses under conditions which result in substantial lysis of the proliferating cells. The methods may include the selective removal of immune constituents that may interfere with the systemic delivery of the virus; preventing reovirus recognition by the host immune system; and removal of the virus from an immune suppressed or immune incompetent host following treatment with reovirus. Alternatively, reovirus may be administered to a mammal with a diminished immune response system under conditions which result in substantial lysis of the proliferating cells.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 5023252 (1991-06-01), Hseih
patent: 6136307 (2000-10-01), Lee et al.
patent: 6565831 (2003-05-01), Coffey et al.
patent: 0453242 (1991-10-01), None
patent: 0514603 (1992-11-01), None
patent: 90/09441 (1990-08-01), None
patent: 90/11765 (1990-10-01), None
patent: 94/18992 (1994-09-01), None
patent: 97/04805 (1997-02-01), None
patent: 97/16443 (1997-05-01), None
patent: 98/08541 (1998-03-01), None
patent: 99/08692 (1999-02-01), None
patent: 99/18799 (1999-04-01), None
Andreansky, S.S., et al. “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.”Proc. Natl. Acad. Sci. USA. 93:11313-11318 (1996).
Armstrong, G.D. et al., “Studies on Reovirus Receptors of L Cells: Virus Binding Characteristics and Comparison with Reovirus Receptors of Erythrocytes.”Virology138:37-48 (1984).
Aronheim, A., et al. “Membrane Targeting of the Nucleotide Exchange Factor Sos is Sufficient for Activating the Ras Signaling Pathway.”Cell, 78:949-961 (1994).
Avruch, J., et al. “Raf meets Ras: completing the framework of a signal transduction pathway.”Trends Bioch. Sci. 19:279 (1994).
Baldari, C.T., et al. “Interleukin-2 Promoter Activation in T-Cells Expressing Activated Ha-ras.”The J. of Biological Chemistry. 267(7): 4289-4291 (1992).
Barbacid, M., “ras Genes.”Annu. Rev. Biochem., 56:779-827 (1987).
Berrozpe, G., et al. “Comparative Analysis of Mutations in thep53and K-rasGenes in Pancreatic Cancer.”Int. J. Cancer, 58:185-191 (1994).
Bischoff, J.R., et al. “Mechanism of Interferon Action.”Virology172:106-115 (1989).
Bollag G., et al., “Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells”,Nature12(2):144-148, abstract (1996).
Bos, J. “rasOncogenes in Human Cancer: A Review.”Cancer Res. 49:4682 (1989).
Boviatsis, E.J., et al. “Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simples virus vectors defective in thymidine kinase or ribonucleotide reductase.”Gene Therapy. 1:323-331 (1994).
Bryson, J.S., et al. “Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia.”Cancer Immunol. Immunother. 26:132-138 (1988).
Cahill, M.A., et al., “Signalling pathways: Jack of all cascades.”Curr. Biol., 6:16-19 (1996).
Coffey, M.C. et al., “Reovirus therapy of tumors with activated Ras pathway”,Science282(5392):1332-1334 (1998).
Chambers, R., et al. “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in ascidmouse model of human malignant glioma.”Proc. Natl. Acad. Sci. USA. 92:1411-1415 (1995).
Chandran, K., et al. “Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle”,J. of Virology72(1):467-75 (1998).
Chaubert, P. “K-ras Mutations and p53 Alterations in Neoplastic and Nonneoplastic Lesions associated with Longstanding Ulcerative Colitis.” et al.Am. J. Path. 144:767 (1994).
Cuff et al., “Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract”Toxicological Sciences42(2):99-108 (1998).
Der, S.D., et al. “A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis.”Proc. Natl. Acad. Sci. USA94:3279-3283 (1997).
Dudley, D.T., et al. “A synthetic inhibitor or the mitogen-activated protein kinase cascade.”Proc. Natl. Acad. Sci. USA92:7686-7689 (1995).
Duncan, et al. “Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein”Virology182(2):810-9 (1991).
Duncan, et al. “Differential Sensitivity of Normal and Transformed Human Cells to Reovirus Infection.”J. of Virol. 28(2):444-449 (1978).
Gale, Jr., et al. “Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.”Virology. 230:217-227 (1997).
Gentsch, J.R.K. et al., “Effect of Neuraminidase Treatment of Cells and Effect of Soluble Glycoproteins on Type 3 Reovirus Attachment to Murine L Cells.”J. Virol. 56 (2):356 (1985).
Hall-Jackson, C.A., et al., “Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: A potential therapeutic target”British Journal of Cancer78(5):641-651 (1998).
Hashiro, et al. “The Preferential Cytotoxicity of Reovirus for certain transformed cell lines.”Archives of Virology54(4): 307-315 (1977).
He, et al. “Suppression of the phenotype of γ134.5—herpes simplex virus 1: Failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the α47 Gene.”J. of Birol. 71(8):6049-6054 (1997).
Helbing, C.C. et al. “A Novel Candidate Tumor Suppressor,ING1, is Involved in the Regulation of Apoptosis.”Cancer Res. 57:1255-1258 (1997).
Hershey, J.W.B. “Translational Control in Mammalian Cells.”Annu. Rev. Biochem. 60:717-755 (1991).
Hu, Y., et al. “2-Aminopurine Inhibits the Double-Stranded RNA-Dependent Protein Kinase Both In Vitro and In Vivo.”J. Interferon Res. 13:323-328 (1993).
Ikeda, K., et al., “Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses”,Nature Medicine, vol. 5, No. 8 (1999) 881-887.
Ikeda, K., et al., “Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant”,Jr. Virology, vol. 74, No. 10 (2000) 4765-4775.
Janes, P.W., et al. “Activation of the Ras signalling pathway in human breast cancel cells overexpressingerbB-2.”Oncogene9:3601-3608 (1994).
Kawagishi-Kobayashi, et al. “Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate 3IF2α.”Mol. and Cell. Biol. 17(7):4146-4158 (1997).
Kirn D.H. et al., “Replicating viruses as selective cancer therapeutics”Molecular Medicine Today, vol. 2, No. 12 (1996) 519-527.
Kollermorgen, G.M., et al. “Immunotherapy of EL4 Lymphoma with Reovirus.”Cancer Immunol. Immunother. 1:239-244 (1976).
Laemmli, U.K. “Cleavage of Structural Proteins dueing the Assembly of the Head of Bacteriophage T4.”Nature227:680-685 (1970).
Lee. J.M. et al. “p53 mutations increase resistance to ionizing radiation.”PNAS90:5742-5746 (1993).
Lee, P.W.K. et al. “Characterization of Anti-Reovirus Immunoglobulins Secreted by Cloned Hybridoma Cell Lines.”Virol
Coffey Matthew C.
Thompson Bradley G.
Fish & Richardson P.C.
Housel James
Li Baoqun
Oncolytics Biotech Inc.
LandOfFree
Methods for preventing reovirus recognition for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preventing reovirus recognition for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preventing reovirus recognition for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3612163